Prelude Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Stock-Based Compensation Growth & History (PRLD)
Prelude Therapeutics's stock-based compensation was $11.9M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.9M | −$9.4M | −44.19% |
| 2024 | 2024-12-31 | $21.3M | −$4.3M | −16.67% |
| 2023 | 2023-12-31 | $25.6M | $472,000 | +1.88% |
| 2022 | 2022-12-31 | $25.1M | $4.2M | +20.13% |
| 2021 | 2021-12-31 | $20.9M | $15.3M | +274.91% |
| 2020 | 2020-12-31 | $5.6M | $4.7M | +559.93% |
| 2019 | 2019-12-31 | $846,000 | — | — |
Prelude Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.0M | −$1.8M | −46.85% |
| Q1 2026 | 2026-03-31 | $2.0M | −$1.8M | −47.81% |
| Q4 2025 | 2025-12-31 | $1.8M | −$1.9M | −51.14% |
| Q3 2025 | 2025-09-30 | $2.4M | −$3.5M | −59.11% |
| Q2 2025 | 2025-06-30 | $3.8M | −$2.3M | −37.45% |
| Q1 2025 | 2025-03-31 | $3.8M | −$1.7M | −30.92% |
| Q4 2024 | 2024-12-31 | $3.8M | −$2.1M | −36.16% |
| Q3 2024 | 2024-09-30 | $5.9M | −$789,000 | −11.75% |
| Q2 2024 | 2024-06-30 | $6.1M | −$635,000 | −9.43% |
| Q1 2024 | 2024-03-31 | $5.5M | −$709,000 | −11.33% |
| Q4 2023 | 2023-12-31 | $5.9M | $67,000 | +1.15% |
| Q3 2023 | 2023-09-30 | $6.7M | $273,000 | +4.24% |
| Q2 2023 | 2023-06-30 | $6.7M | $705,000 | +11.70% |
| Q1 2023 | 2023-03-31 | $6.3M | −$573,000 | −8.39% |
| Q4 2022 | 2022-12-31 | $5.8M | $70,000 | +1.21% |
| Q3 2022 | 2022-09-30 | $6.4M | −$591,000 | −8.40% |
| Q2 2022 | 2022-06-30 | $6.0M | $1.8M | +42.27% |
| Q1 2022 | 2022-03-31 | $6.8M | $2.9M | +75.73% |
| Q4 2021 | 2021-12-31 | $5.8M | $2.7M | +84.98% |
| Q3 2021 | 2021-09-30 | $7.0M | $5.6M | +377.79% |
| Q2 2021 | 2021-06-30 | $4.2M | $3.6M | +575.76% |
| Q1 2021 | 2021-03-31 | $3.9M | $3.5M | +973.48% |
| Q4 2020 | 2020-12-31 | $3.1M | — | — |
| Q3 2020 | 2020-09-30 | $1.5M | $1.2M | +395.62% |
| Q2 2020 | 2020-06-30 | $627,000 | — | — |
| Q1 2020 | 2020-03-31 | $362,000 | — | — |
| Q3 2019 | 2019-09-30 | $297,000 | — | — |
Prelude Therapeutics stock-based compensation trends
Over the last five fiscal years, Prelude Therapeutics's stock-based compensation increased from $5.6M to $11.9M, a change of $6.3M. The latest reported quarter, Q2 2026, shows $2.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...